KUKJEON Co.,Ltd
Founded in 2018, KUKJEON supplies APIs through synthesis manufacturing and advanced materials like HBM additives for semiconductors and displays.
As of 2026-10-10, KUKJEON Co.,Ltd has 1 PubMed-indexed paper on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded and listed on KOSDAQ in 2018, KUKJEON is an API and advanced-materials company that renamed itself from Kukjeon Pharm to KUKJEON as its business expanded. Its pharmaceutical segment synthesizes, imports, distributes, and sells active pharmaceutical ingredients (APIs), while its materials segment supplies high-purity functional additives for HBM manufacturing, antistatic agents, and OLED common-layer materials for advanced industries. Its oral dementia drug candidate HY-209, in-licensed from Chaperone (378800), is nearing completion of Phase 1 trials, its hypertension-diabetes combination drug THP-001, co-developed with THPharm, is in Phase 3, and consolidated revenue fell 3.98% year-on-year.
Products & technology
- Active Pharmaceutical Ingredients (API)Synthesis manufacturing, import/distribution, and sale of APIs for generics, new drugs, and improved new drugs
- High-purity functional additives for HBM manufacturingMaterials for AI semiconductor packaging processes
- Antistatic agentsChemical materials for advanced industries
- OLED common-layer materialsMaterials for OLED displays
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1 · Unknown · 2023-09 · NCT06533878
R&D and key agreements
Source: DART corporate disclosureHY-209(경구용 치매치료제) · 치매 · 임상1상 종료 예정 · In-licensed from Chaperone (378800) and co-developed
THP-001(고혈압·당뇨 복합제) · 고혈압, 당뇨 · 임상3상 · Co-developed with THPharm
제네릭 개발 프로젝트 · Multiple generic items under development in collaboration with client companies via the in-house pharmaceutical research institute
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Effectiveness of Korean medicine treatments in improving cognitive function and prefrontal cortex activity in older individuals with mild cognitive impairment: retrospective observational study.
Frontiers in neurology · 2024-01 · Choi Y, Lee K, Yang C 외 3
Patents
KIPRIS · applicant-matched- Subsidiary: 주식회사 국전에프앤디인공지능 기반 의약품 허가 보고서 검증 시스템 및 방법
Published · 2024-08 · Application 1020240103131
- Subsidiary: 주식회사 국전에프앤디인공지능 기반 의약품 허가 보고서 생성 시스템 및 방법
Published · 2024-08 · Application 1020240103132
Rejected · 2024-02 · Application 1020240030169
Rejected · 2023-12 · Application 1020230186975
Published · 2023-09 · Application 1020230123762
Rejected · 2023-07 · Application 1020230087386
Registered · 2022-10 · Application 1020220129579
- Subsidiary: 에니솔루션 주식회사위장질환 치료용 복합정제
Rejected · 2022-05 · Application 1020220055873
Registered · 2022-01 · Application 1020220011010
PCT · Published · 2022-01 · Application PCT/KR2022/001215
Show 11 more patents
Registered · 2022-01 · Application 1020220000673
Registered · 2021-11 · Application 1020210157172
Registered · 2021-09 · Application 1020210126600
Rejected · 2021-09 · Application 1020210117491
Registered · 2021-08 · Application 1020210107805
- Subsidiary: 에니솔루션 주식회사리라글루타이드를 함유하는 마이크로니들 제조용 조성물
Withdrawn · 2021-05 · Application 1020210059403
Withdrawn · 2021-01 · Application 1020210012880
Registered · 2021-01 · Application 1020210011477
Rejected · 2020-12 · Application 1020200182538
Registered · 2019-01 · Application 1020190004981
Registered · 2018-04 · Application 1020180047495
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- GoogleGoogleOther2
- AnthropicClaudeBot2
- OpenAIOAI-SearchBot1
- MicrosoftBingbot1
- PerplexityPerplexityBot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 1, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for KUKJEON Co.,Ltd and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition